510 related articles for article (PubMed ID: 27565569)
21. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study.
de Sanjose S; Quint WG; Alemany L; Geraets DT; Klaustermeier JE; Lloveras B; Tous S; Felix A; Bravo LE; Shin HR; Vallejos CS; de Ruiz PA; Lima MA; Guimera N; Clavero O; Alejo M; Llombart-Bosch A; Cheng-Yang C; Tatti SA; Kasamatsu E; Iljazovic E; Odida M; Prado R; Seoud M; Grce M; Usubutun A; Jain A; Suarez GA; Lombardi LE; Banjo A; Menéndez C; Domingo EJ; Velasco J; Nessa A; Chichareon SC; Qiao YL; Lerma E; Garland SM; Sasagawa T; Ferrera A; Hammouda D; Mariani L; Pelayo A; Steiner I; Oliva E; Meijer CJ; Al-Jassar WF; Cruz E; Wright TC; Puras A; Llave CL; Tzardi M; Agorastos T; Garcia-Barriola V; Clavel C; Ordi J; Andújar M; Castellsagué X; Sánchez GI; Nowakowski AM; Bornstein J; Muñoz N; Bosch FX;
Lancet Oncol; 2010 Nov; 11(11):1048-56. PubMed ID: 20952254
[TBL] [Abstract][Full Text] [Related]
22. [Prevalence of human papillomavirus in Spanish women from a population screening program].
García S; Dominguez-Gil M; Gayete J; Rojo S; Muñoz JL; Salas JS; Echevarria C; Blanco M; Ramos C; De Frutos M; López-Urrutia L; Viñuela L; Tamames S; Redondo P; Jiménez JM; Eiros JM; Ortiz de Lejarazu R
Rev Esp Quimioter; 2017 Jun; 30(3):177-182. PubMed ID: 28508620
[TBL] [Abstract][Full Text] [Related]
23. Prevalence of vaccine and non-vaccine human papillomavirus types among women in Accra and Kumasi, Ghana: a cross-sectional study.
Debrah O; Agyemang-Yeboah F; Donkoh ET; Asmah RH
BMC Womens Health; 2021 Oct; 21(1):372. PubMed ID: 34702246
[TBL] [Abstract][Full Text] [Related]
24. High prevalence of cervical high-risk human papillomavirus infection mostly covered by Gardasil-9 prophylactic vaccine in adult women living in N'Djamena, Chad.
Mboumba Bouassa RS; Nodjikouambaye ZA; Sadjoli D; Adawaye C; Péré H; Veyer D; Matta M; Robin L; Tonen-Wolyec S; Moussa AM; Koyalta D; Belec L
PLoS One; 2019; 14(6):e0217486. PubMed ID: 31158254
[TBL] [Abstract][Full Text] [Related]
25. Prevalence of human papillomavirus types 6, 11, 16 and 18 in young Austrian women - baseline data of a phase III vaccine trial.
Six L; Leodolter S; Sings HL; Barr E; Haupt R; Joura EA
Wien Klin Wochenschr; 2008; 120(21-22):666-71. PubMed ID: 19116707
[TBL] [Abstract][Full Text] [Related]
26. Monitoring vaccine and non-vaccine HPV type prevalence in the post-vaccination era in women living in the Basilicata region, Italy.
Carozzi F; Puliti D; Ocello C; Anastasio PS; Moliterni EA; Perinetti E; Serradell L; Burroni E; Confortini M; Mantellini P; Zappa M; Dominiak-Felden G
BMC Infect Dis; 2018 Jan; 18(1):38. PubMed ID: 29334901
[TBL] [Abstract][Full Text] [Related]
27. Age-specific HPV prevalence among 116,052 women in Australia's renewed cervical screening program: A new tool for monitoring vaccine impact.
Brotherton JM; Hawkes D; Sultana F; Malloy MJ; Machalek DA; Smith MA; Garland SM; Saville M
Vaccine; 2019 Jan; 37(3):412-416. PubMed ID: 30551987
[TBL] [Abstract][Full Text] [Related]
28. Epidemiology of HPV infection and current status of cervical cancer prevention in Greece: final results of the LYSISTRATA cross-sectional study.
Agorastos T; Chatzistamatiou K; Zafrakas M; Siamanta V; Katsamagkas T; Constantinidis TC; Lampropoulos AF;
Eur J Cancer Prev; 2014 Sep; 23(5):425-31. PubMed ID: 24977385
[TBL] [Abstract][Full Text] [Related]
29. Final analysis of a study assessing genital human papillomavirus genoprevalence in young Australian women, following eight years of a national vaccination program.
Garland SM; Cornall AM; Brotherton JML; Wark JD; Malloy MJ; Tabrizi SN;
Vaccine; 2018 May; 36(23):3221-3230. PubMed ID: 29724506
[TBL] [Abstract][Full Text] [Related]
30. Prevalence and risk factors for cervical HPV infection and abnormalities in young adult women at enrolment in the multinational PATRICIA trial.
Roset Bahmanyar E; Paavonen J; Naud P; Salmerón J; Chow SN; Apter D; Kitchener H; Castellsagué X; Teixeira JC; Skinner SR; Jaisamrarn U; Limson GA; Garland SM; Szarewski A; Romanowski B; Aoki F; Schwarz TF; Poppe WA; De Carvalho NS; Harper DM; Bosch FX; Raillard A; Descamps D; Struyf F; Lehtinen M; Dubin G;
Gynecol Oncol; 2012 Dec; 127(3):440-50. PubMed ID: 22940493
[TBL] [Abstract][Full Text] [Related]
31. Impact of HPV vaccination with Gardasil® in Switzerland.
Jacot-Guillarmod M; Pasquier J; Greub G; Bongiovanni M; Achtari C; Sahli R
BMC Infect Dis; 2017 Dec; 17(1):790. PubMed ID: 29273004
[TBL] [Abstract][Full Text] [Related]
32. Age-specific and genotype-specific carcinogenic human papillomavirus prevalence in a country with a high cervical cancer burden: results of a cross-sectional study in Estonia.
Pärna K; Nygård M; Tisler A; Toompere K; Naaber P; Ratnik K; Ķīvīte Urtāne A; Zodzika J; Stankūnas M; Baltzer N; Uusküla A
BMJ Open; 2023 Jun; 13(6):e069558. PubMed ID: 37263686
[TBL] [Abstract][Full Text] [Related]
33. Prevalence and genotype-specific distribution of human papillomavirus in Burundi according to HIV status and urban or rural residence and its implications for control.
Ndizeye Z; Vanden Broeck D; Lebelo RL; Bogers J; Benoy I; Van Geertruyden JP
PLoS One; 2019; 14(6):e0209303. PubMed ID: 31237894
[TBL] [Abstract][Full Text] [Related]
34. Epidemiology and genotype distribution of human papillomavirus (HPV) in women of Sardinia (Italy).
Masia G; Mazzoleni AP; Contu G; Laconi S; Minerba L; Montixi S; Montis F; Onano A; Porcedda E; Coppola RC
Vaccine; 2009 May; 27 Suppl 1():A11-6. PubMed ID: 19480954
[TBL] [Abstract][Full Text] [Related]
35. Prevalence and genotype distribution of cervical human papillomavirus (HPV) among women in urban Tianjin, China.
Chen X; Wallin KL; Duan M; Gharizadeh B; Zheng B; Qu P
J Med Virol; 2015 Nov; 87(11):1966-72. PubMed ID: 26073652
[TBL] [Abstract][Full Text] [Related]
36. Knowledge, attitudes, and practices toward cervical cancer prevention among women in Kampong Speu Province, Cambodia.
Touch S; Oh JK
BMC Cancer; 2018 Mar; 18(1):294. PubMed ID: 29544466
[TBL] [Abstract][Full Text] [Related]
37. Prevalence and Risk Factors of Human Papillomavirus Infection in 18-Year-Old Women: Baseline Report of a Prospective Study on Human Papillomavirus Vaccine.
Igidbashian S; Boveri S; Bottari F; Vidal Urbinati A; Preti E; Casadio C; Landoni F; Sideri M; Sandri MT
J Low Genit Tract Dis; 2017 Jan; 21(1):4-8. PubMed ID: 27755229
[TBL] [Abstract][Full Text] [Related]
38. Would young women attending sexually transmitted disease clinics benefit from human papillomavirus vaccination? An assessment of human papillomavirus DNA and seropositivity from human papillomavirus sentinel surveillance, 2003-2005.
Dunne EF; Flagg EW; Unger ER; Hsu K; Ghanen K; Kerndt P; Shlay JC; Koutsky LA; Datta DS; Panicker G; Zaidi A; Weinstock H; Markowitz LE
Sex Transm Dis; 2014 Jan; 41(1):46-9. PubMed ID: 24326582
[TBL] [Abstract][Full Text] [Related]
39. Decline of HPV infections in Scandinavian cervical screening populations after introduction of HPV vaccination programs.
Dillner J; Nygård M; Munk C; Hortlund M; Hansen BT; Lagheden C; Liaw KL; Kjaer SK
Vaccine; 2018 Jun; 36(26):3820-3829. PubMed ID: 29778519
[TBL] [Abstract][Full Text] [Related]
40. Prevalence and Distribution of Vaccine-Preventable Genital Human Papillomavirus(HPV) Genotypes in Ghanaian Women Presenting for Screening.
Donkoh ET; Asmah RH; Agyemang-Yeboah F; Dabo EO; Wiredu EK
Cancer Control; 2022; 29():10732748221094721. PubMed ID: 35536890
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
